---
title: "Childhood type 1 diabetes incidence fell after Finland’s COVID-19 lockdown peak"
id: "plos-medicine-0-trends-in-the-incidence-of-childhood-type-1-diabetes-after-the-covid-19"
canonical_url: "https://medichelpline.com/clinical-feed/plos-medicine-0-trends-in-the-incidence-of-childhood-type-1-diabetes-after-the-covid-19"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "PLOS Medicine"
source_url: "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288"
published_at: "2026-11-02T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Childhood type 1 diabetes incidence fell after Finland’s COVID-19 lockdown peak
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-medicine-0-trends-in-the-incidence-of-childhood-type-1-diabetes-after-the-covid-19
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** PLOS Medicine
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288)
- **Published At:** 2026-11-02T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators compared **type 1 diabetes** incidence in Finnish children <15 years across three periods: pre-pandemic (three 18-month terms, 2014–2019), lockdown (03/2020–08/2021), and post-lockdown (09/2021–12/2022). - The temporal cohort comprised 3,467 pediatric cases: 2,096 pre-pandemic, 785 during lockdown, and 586 after lockdown. - Data indicated a 15% reduction in incidence after lockdown compared with the lockdown period (IRR 0.85; 95% CI 0.77–0.95; p = 0.004). - The post-lockdown incidence did not differ from pre-pandemic baseline (IRR 1.00; 95% CI 0.91–1.09; p = 0.932). - Investigators combined COVID-19 vaccination records with serology to identify prior **SARS-CoV-2** exposure; infection-associated antibody positivity rose from 0.9% during lockdown to over 40% after reopening. - Authors observed contrasting temporal patterns: a peak in disease incidence during lockdown while seroprevalence climbed only after society reopened. - The study team noted two main limitations: a relatively short post-lockdown follow-up and absence of explicit modeling for the long-term secular trend in **type 1 diabetes** incidence. - The authors concluded the findings are compatible with an indirect role for the virus or pandemic-related societal factors in the observed incidence changes, but direct causation by **SARS-CoV-2** is not supported by the temporal serology pattern.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosmedicine%2Farticle%3Fid%3D10.1371%2Fjournal.pmed.1005288) * * About * Browse * Publish * [](https://journals.plos.org/plosmedicine/ "PLOS Medicine") * Search [advanced search](https://journals.plos.org/plosmedicine/search) * 0 [Save](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288#savedHeader) [Total Mendeley and Citeulike bookmarks.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288#savedHeader) * 0 [Citation](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288#citedHeader) [Paper's citation count computed by Dimensions.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288#citedHeader) * 40 [View](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288#viewedHeader) [PLOS views and downloads.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288#viewedHeader) * 0 [Share](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288#discussedHeader) [Sum of Facebook, Twitter, Reddit and Wikipedia activity.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288#discussedHeader) Open Access Peer-reviewed Research Article # Trends in the incidence of childhood type 1 diabetes after the COVID-19 lockdown in Finland: An observational study * Susanna Tall , Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Validation, Visualization, Writing – original draft * E-mail: susanna.tall@helsinki.fi Affiliations Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland, Department of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-3746-4728 ](https://orcid.org/0000-0002-3746-4728 "ORCID Registry") ⨯ * Maaret Turtinen, Roles Data curation, Methodology, Writing – review & editing Affiliations Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland, Pediatric Research Center, New Children’s Hospital, Helsinki University Hospital, Helsinki, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0009-0004-8809-6867 ](https://orcid.org/0009-0004-8809-6867 "ORCID Registry") ⨯ * Anna Parviainen, Roles Data curation, Methodology, Writing – review & editing Affiliations Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland, Pediatric Research Center, New Children’s Hospital, Helsinki University Hospital, Helsinki, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-6466-0126 ](https://orcid.org/0000-0002-6466-0126 "ORCID Registry") ⨯ * Jenni Pettersson, Roles Conceptualization, Data curation, Formal analysis, Methodology, Visualization, Writing – review & editing Affiliations Department of Virology, Medicum, University of Helsinki, Helsinki, Finland, Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-6518-3088 ](https://orcid.org/0000-0001-6518-3088 "ORCID Registry") ⨯ * Anna But, Roles Formal analysis, Methodology, Writing – review & editing Affiliation Biostatistics Consulting, Department of Public Health, Helsinki University Hospital, University of Helsinki, Helsinki, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-0259-8224 ](https://orcid.org/0000-0002-0259-8224 "ORCID Registry") ⨯ * Taina Härkönen, Roles Formal analysis, Methodology, Writing – review & editing Affiliation Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland ⨯ * Jussi Hepojoki, Roles Formal analysis, Investigation, Methodology, Writing – review & editing Affiliation Department of Virology, Medicum, University of Helsinki, Helsinki, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-5699-214X ](https://orcid.org/0000-0001-5699-214X "ORCID Registry") ⨯ * Tarja Sironen, Roles Formal analysis, Investigation, Methodology, Writing – review & editing Affiliations Department of Virology, Medicum, University of Helsinki, Helsinki, Finland, Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland ⨯ * Rommel Iheozor-Ejiofor, Roles Formal analysis, Investigation, Methodology, Writing – review & editing Affiliation Department of Virology, Medicum, University of Helsinki, Helsinki, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-7654-5515 ](https://orcid.org/0000-0001-7654-5515 "ORCID Registry") ⨯ * Hasan Uğurlu, Roles Formal analysis, Investigation, Methodology, Writing – review & editing Affiliation Erzurum Technical University, Erzurum, Turkey [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-3849-7847 ](https://orcid.org/0000-0002-3849-7847 "ORCID Registry") ⨯ * Kalle Saksela, Roles Formal analysis, Investigation, Methodology, Writing – review & editing Affiliations Department of Virology, Medicum, University of Helsinki, Helsinki, Finland, Virology and Immunology, Helsinki University Hospital Diagnostic Center, Helsinki, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0003-0827-122X ](https://orcid.org/0000-0003-0827-122X "ORCID Registry") ⨯ * Jorma Ilonen, Roles Formal analysis, Investigation, Methodology, Writing – review & editing Affiliation Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland ⨯ * Suvi M. Virtanen, Roles Conceptualization, Supervision, Writing – review & editing Affiliations Department of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland, Tampere Center for Child, Adolescent and Maternal Health Research, Tampere University and Tampere University Hospital, Tampere, Finland, Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland, Faculty of Social Sciences, Unit of Health Sciences, Tampere University, Tampere, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-8928-0878 ](https://orcid.org/0000-0001-8928-0878 "ORCID Registry") ⨯ * Olli Vapalahti, Roles Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing – review & editing Affiliations Department of Virology, Medicum, University of Helsinki, Helsinki, Finland, Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland, Virology and Immunology, Helsinki University Hospital Diagnostic Center, Helsinki, Finland ⨯ * Mikael Knip, Roles Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – review & editing Affiliations Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland, Pediatric Research Center, New Children’s Hospital, Helsinki University Hospital, Helsinki, Finland, Tampere Center for Child, Adolescent and Maternal Health Research, Tampere University and Tampere University Hospital, Tampere, Finland, Turku, Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0003-0474-0033 ](https://orcid.org/0000-0003-0474-0033 "ORCID Registry") ⨯ * [ ... ], * on behalf of the Finnish Pediatric Diabetes Register ¶Membership of the Finnish Pediatric Diabetes Register is provided in the S1 Text. ⨯ * [ view all ] * [ view less ] # Trends in the incidence of childhood type 1 diabetes after the COVID-19 lockdown in Finland: An observational study * Susanna Tall, * Maaret Turtinen, * Anna Parviainen, * Jenni Pettersson, * Anna But, * Taina Härkönen, * Jussi Hepojoki, * Tarja Sironen, … * Rommel Iheozor-Ejiofor, * Hasan Uğurlu ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: November 2, 2026 * * [Article](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288) * [Authors](https://journals.plos.org/plosmedicine/article/authors?id=10.1371/journal.pmed.1005288) * [Metrics](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005288) * [Comments](https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1005288) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pmed.1005288) * [Peer Review](https://journals.plos.org/plosmedicine/article/peerReview?id=10.1371/journal.pmed.1005288) * [Abstract](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#abstract0) * [Author summary](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#abstract1) * [Introduction](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#sec007) * [Methods](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#sec008) * [Results](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#sec013) * [Discussion](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#sec018) * [Supporting information](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#sec019) * [Acknowledgments](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#ack) * [References](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#references) * [Reader Comments](https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1005288) * [Figures](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288) [?](https://journals.plos.org/plosmedicine/s/accepted-manuscripts#loc-early-version) ## This is an uncorrected proof. ## Abstract ### Background While COVID-19 lockdowns have been systematically associated with increased incidence rate of type 1 diabetes, less is known about the disease rates after lockdowns. We compared the incidence of type 1 diabetes after the COVID-19 pandemic-related closure of society (i) to the time when lockdown was implemented and to (ii) the time before the pandemic in Finland. ### Methods and findings The incidence of type 1 diabetes after the lockdown (09/2021–12/2022) was compared to the incidence during the lockdown (03/2020–08/2021) and before the lockdown (three 18-month terms 2014–2019) in Finnish children under the age of 15 years. Previous exposure to SARS-CoV-2 was identified by combining information on COVID-19 vaccination with data on SARS-CoV-2 antibodies analyzed in blood samples. The temporal cohort included 3,467 pediatric type 1 diabetes cases, distributed across post-lockdown (_n_ = 586), lockdown (_n_ = 785), and pre-pandemic (_n_ = 2,096) periods. The incidence of type 1 diabetes after the lockdown was significantly lower than the incidence during the lockdown [incidence rate ratio (IRR = 0.85; 95% Cl [0.77,0.95]; _p =_ 0.004)]. The rate of type 1 diabetes after the lockdown did not significantly differ from the time before lockdown (IRR = 1.00; 95% Cl [0.91,1.09]; _p_ = 0.932). The frequency of children testing positive for infection-associated SARS-CoV-2 antibodies increased from 0.9% during the lockdown to more than 40% after the lockdown. Study limitations include a relatively short follow-up period after the lockdown and the lack of explicit modeling of the underlying long-term secular trend in type 1 diabetes incidence. ### Conclusions The lockdown represents a peak in childhood type 1 diabetes incidence in Finland compared to both the pre-pandemic and post-lockdown periods. However, the reversion toward historical levels after the lockdown does not necessarily establish a return to the expected historical trajectory, nor can it fully distinguish a transient change from temporal compensation superimposed on the background secular trend. The contrasting patterns between type 1 diabetes incidence and SARS-CoV-2 antibody prevalence during and after the lockdown suggest an indirect rather than a direct role of the virus in triggering the observed changes in incidence. ## Author summary ### Why was this study done? * The Coronavirus disease 2019 (COVID-19) pandemic has been linked to an increased incidence of type 1 diabetes in numerous research articles. * A few European studies have reported that the surge in type 1 diabetes incidence observed during the 2021 lockdowns did not persist after the reopening of society in 2022. However, studies investigating type 1 diabetes incidence beyond the acute phase of the pandemic remain scarce. ### What did the researchers do and find? * The incidence of type 1 diabetes after the lockdown (09/2021–12/2022) was compared to the incidence during (03/2020–08/2021) and before lockdown (three 18-month terms 2014–2019) in Finnish children under the age of 15 years. * The incidence of type 1 diabetes decreased by 15% among Finnish children during the first 16 months after the COVID-19 lockdown compared with the time when lockdown was implemented. * The incidence after the lockdown was equal compared to the reference time before the COVID-19 pandemic. ### What do these findings mean? * The lockdown represents a peak in type 1 diabetes incidence in Finland, not only compared to the time before lockdown, but also afterwards. * Study limitations include a relatively short follow-up period after the lockdown and the lack of explicit modeling of the underlying long-term secular trend in type 1 diabetes incidence. ## Figures ![Table 2](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005288.t002) ![Fig 1](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005288.g001) ![Table 1](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005288.t001) ![Fig 2](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005288.g002) ![Table 2](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005288.t002) ![Fig 1](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005288.g001) ![Table 1](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005288.t001) ![Fig 2](https://journals.plos.org/plosmedicine/article/figure/image?size=inline&id=10.1371/journal.pmed.1005288.g002) **Citation:** Tall S, Turtinen M, Parviainen A, Pettersson J, But A, Härkönen T, et al. (2026) Trends in the incidence of childhood type 1 diabetes after the COVID-19 lockdown in Finland: An observational study. PLoS Med 23(11): e1005288. https://doi.org/10.1371/journal.pmed.1005288 **Academic Editor:** Weiping Jia, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, CHINA **Received:** March 10, 2026; **Accepted:** October 8, 2026; **Published:** November 2, 2026 **Copyright:** © 2026 Tall et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. **Data Availability:** The aggregated dataset related to the primary incidence outcomes and all author-generated analytical code required to replicate the primary incidence outcomes and secondary clinical models of this study are publicly available in the Zenodo repository at . The individual-level clinical, genetic, and immunologic datasets underlying other reported variables cannot be made publicly available due to strict legal and ethical restrictions under Finnish national law and the European Union General Data Protection Regulation (GDPR). Under the Finnish Act on the Secondary Use of Health and Social Data (552/2019), public dissemination or direct author-sharing of individual-level or pseudonymized registry records is strictly prohibited to prevent patient re-identification. These restricted clinical datasets are accessible to qualified researchers for replication purposes upon obtaining the required regulatory permits: • Data Permit Request: A formal data permit application must be submitted directly to Findata via the official Findata Permit Application Portal (findata.fi) • Analysis Environment: In accordance with Findata infrastructure mandates, raw individual data cannot be downloaded locally; approved researchers are granted remote access within Findata’s secure computing environment (Kapseli). • Institutional Contact: To verify data access criteria or request institutional assistance regarding the Finnish Pediatric Diabetes Register dataset, researchers may contact the University of Helsinki Faculty of Medicine data administration office via email at med-ext-info@helsinki.fi or the Research Programs Unit administration at rpu-admin@helsinki.fi. **Funding:** This study was supported by the University of Helsinki Doctoral School (UHDS), Helsinki University Hospital Research Funds, EU Horizon 2020 (Versatile emerging infectious disease observatory and Long Covids projects), Academy of Finland, Sigrid Jusélius Foundation, Jane & Aatos Erkko Foundation, Medicinska understödsföreningen Liv och Hälsa, the Foundation for Pediatric Research in Finland and the Björkqvist Foundation. **Competing interests:** The authors have declared that no competing interests exist. **Abbreviations:** CI, confidence interval; DKA, Diabetic ketoacidosis; ELISA, enzyme-linked immunosorbent assay; FPDR, Finnish Pediatric Diabetes Register; HLA, human leukocyte antigen; IAA, Insulin autoantibodies; IRR, incidence rate ratios; LLM, Large Language Model; PY, person-years; RU, relative units ## Introduction The Coronavirus disease 2019 (COVID-19) pandemic has been related to an increased incidence of type 1 diabetes in a series of research articles [[1](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#pmed.1005288.ref001)]. A meta-analysis published in 2023 including 17 studies showed a higher incidence rate of type 1 diabetes during the first year of the pandemic compared with the pre-pandemic period [[1](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#pmed.1005288.ref001)]. A few European studies have reported that the 2021 peak in type 1 diabetes incidence did not persist into 2022 [[2](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#pmed.1005288.ref002),[3](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005288#pmed.1005288.ref003)]. Type 1 diabetes incidence in Sweden peaked in 2021 during a period of internationally unique, minimal COVID-19 pandemic-related social di
## Related Clinical Research

- [WHO issues first guidelines on adult type 1 diabetes care](https://medichelpline.com/clinical-feed/who-0-0-who-issues-first-guidelines-on-type-1-diabetes-for-adults.md)
- [Low‑dose estradiol to treat persistent vasomotor symptoms after oophorectomy in a transgender man](https://medichelpline.com/clinical-feed/cmaj-1-estradiol-for-persistent-vasomotor-symptoms-after-surgical-menopause-in-a.md)
- [High blood pressure in Ugandan children and adolescents with Type 1 diabetes: multicenter prevalen](https://medichelpline.com/clinical-feed/plos-one-11-high-blood-pressure-among-children-and-adolescents-with-type-1-diabetes.md)
- [Eating attitudes and glycaemic control in adolescents with Type 1 DM: a cross-sectional analysis](https://medichelpline.com/clinical-feed/plos-one-21-eating-behaviour-and-glycaemic-control-a-cross-sectional-study-in-adolescents.md)
- [Self-monitoring frequency linked to glycaemic control in Kenyan children with Type 1 diabetes](https://medichelpline.com/clinical-feed/medrxiv-10-factors-associated-with-poor-glycaemic-control-among-children-and-adolescents.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.